Oncolytics details GOBLET readout timing; SystImmune starts Phase 3 ADC trial in urothelial cancer
Oncolytics Biotech gave updated timing for GOBLET cohort data and a PanCAN grant payment, while SystImmune began recruiting a Phase 3 trial of T-bren in HER2-expressing metastatic urothelial cancer.
Two separate items this week: a clinical update from Oncolytics Biotech on its ongoing GOBLET study, and a new Phase 3 trial registration from SystImmune.
- Oncolytics Biotech announced an update on its GOBLET Phase 1/2 study and said it will receive the final payment under its grant from the Pancreatic Cancer Action Network later this quarter, following the completion of certain activities in Cohort 5 of the study.1 The company said it expects to report final results from Cohort 4 in the fourth quarter of 2026, while initial results from Cohort 5 are expected in the first half of 2027, though timing could extend as patients continue treatment and follow-up.1
- SystImmune Inc. is recruiting for a Phase 3 trial (NCT07869836) comparing its antibody drug conjugate T-bren (BL M07D1) against platinum-based chemotherapy in patients with HER2 expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy.2 The study plans to enroll 520 participants2 with a primary endpoint of progression-free survival by Blinded Independent Central Review per RECIST v1.1 in the primary population.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.